ライフサイエンスコーパス: braziliensis

1 risk for CL development caused by Leishmania braziliensis.

2 d an effective treatment for CL caused by L. braziliensis.

3 reatment of tegumentary disease caused by L. braziliensis.

4 eous leishmaniasis (CL) caused by Leishmania braziliensis.

5 bundant in skin lesions caused by Leishmania braziliensis.

6 cutaneous leishmaniasis caused by Leishmania braziliensis.

7 brucei and to a lesser extent in Leishmania braziliensis.

8 the clinical course of diseases caused by L. braziliensis.

9 ed with the prevalent related species L.(V.) braziliensis.

10 we characterized DCs that were exposed to L. braziliensis.

11 ishmania: Leishmania infantum and Leishmania braziliensis.

12 to LCTAS, were isolated and mapped onto a L. braziliensis 250 kb multicopy minichromosome and the L.

13 interleukin-4 than did mice infected with L. braziliensis alone.

14 Here we show that ROS inhibits growth of L. braziliensis amastigotes in resting monocytes, and that

15 Monocytes from PBMC were infected with L. braziliensis and cocultured with CD8(+) T cells, and the

16 Patients coinfected with Leishmania braziliensis and helminths took longer to heal (relative

17 For both L. braziliensis and L. guyanensis, RNAi-derived LRV1-negati

18 S in the telomeric region differs between L. braziliensis and L. major: in L. major the LCTASs are ta

19 d with drug-treatment failures in Leishmania braziliensis and Leishmania guyanensis infections.

20 ll RNAs derived from LRV1 in both Leishmania braziliensis and Leishmania guyanensis, mapping across b

21 results against Trypnosoma cruzi, Leishmania braziliensis and Leishmania infantum were not clinically

22 300 telomere-derived clones from Leishmania braziliensis and Leishmania major, a conserved 100 bp se

23 Dogs from an area of Leishmania braziliensis and Leishmania peruviana endemicity were sc

24 nuclear cells from patients infected with L. braziliensis and reduced IL-1beta levels after cure.

25 cessfully generated axenic amastigotes of L. braziliensis and used them to test the hypothesis that L

26 second Brazilian sample (also exposed to L. braziliensis) and in Iranians infected with Leishmania t

27 Lutzomyia intermedia, a vector of Leishmania braziliensis, and evaluated the seroreactivity in expose

28 hmania (Leishmania) amazonensis, L (Viannia) braziliensis, and L (V) guyanensis] and samples from pat

29 were established, parasites were typed as L. braziliensis, and the presence of LRV1 was determined by

30 th cutaneous leishmaniasis due to Leishmania braziliensis are CD4(+)CD25(-)CD127(-/low)FOXP3(-) cells

31 rd against which future interventions for L. braziliensis are compared.

32 Leishmania braziliensis are intracellular parasites that cause uniq

33 interfering RNAs (siRNAs) associated with L. braziliensis Argonaute1 (LbrAGO1).

34 are of patients with CL caused by Leishmania braziliensis, because screening for and treatment of hel

35 ows that ROS are important for control of L. braziliensis both at the initial stages of infection, as

36 Leishmania major and Leishmania braziliensis both cause cutaneous leishmaniasis, but the

37 ric oxide, also contributed to killing of L. braziliensis by IFN-gamma activated monocytes.

38 The control of Leishmania braziliensis by individuals with subclinical infection (

39 (V.) braziliensis by the parasitologic approach; for the othe

40 Leishmania (Viannia) braziliensis can cause localized cutaneous leishmaniasis

41 Leishmania (Viannia) braziliensis causes localized cutaneous leishmaniasis (L

42 in the peripheral blood of patients with L. braziliensis, compared with uninfected controls.

43 L. braziliensis, contrary to Leishmania species examined so

44 LRV-1-positive L.V. braziliensis demonstrated significantly lower expression

45 ed Leishmania proteins, Leishmania (Viannia) braziliensis-derived Lb8E and Lb6H, and evaluated both i

46 that human patients infected with Leishmania braziliensis develop dysbiotic skin microbiota, characte

47 Many isolates of L. braziliensis (>25%) contain a double-stranded RNA virus

48 ngle lesions due to Bolivian Leishmania (v.) braziliensis in a placebo-controlled study.

49 eous leishmaniasis (CL) caused by Leishmania braziliensis in Brazil with pentavalent antimony (Sb(v))

50 The assay detected L. braziliensis in dermal scrapings from cutaneous leishman

51 eous leishmaniasis patients infected with L. braziliensis in Rio de Janeiro, Brazil, an area where th

52 dy, the role of AnxA1 was investigated in L. braziliensis-infected BALB/c mice.

53 The chemoattractant factors secreted by L. braziliensis-infected cells were highly efficient in rec

54 wide transcriptional profiling of Leishmania braziliensis-infected cutaneous lesions and normal skin

55 In contrast, L. braziliensis-infected DCs failed to up-regulate activati

56 ood mononuclear cells (PBMC) from Leishmania braziliensis-infected human patients have demonstrated t

57 cytokines and prime naive CD4(+) T cells, L. braziliensis-infected MyD88(-/-) DCs exhibited less acti

58 drug treatment success and disease in 97 L. braziliensis-infected patients from Peru and Bolivia.

59 As such, L. braziliensis-infected TLR2(-/-) DCs were more competent

60 We have previously reported that Leishmania braziliensis infection can activate murine dendritic cel

61 of inflammatory mediators in response to L. braziliensis infection contributes to cell recruitment a

62 and used them to test the hypothesis that L. braziliensis infection efficiently triggers innate respo

63 We observed that while L. braziliensis infection induced the production of chemoki

64 Cutaneous leishmaniasis due to Leishmania braziliensis infection is an inflammatory disease in whi

65 AnxA1 increased also after L. braziliensis infection of BALB/c (wild-type [WT]) bone m

66 Secondly, L. braziliensis infection triggered transcription and phosp

67 Our results suggest that, following L. braziliensis infection, the production of multiple infla

68 e that AnxA1 is actively expressed during L. braziliensis infection.

69 -up, 118 subjects (38.3%) had evidence of L. braziliensis infection.

70 tion against Leishmania major and Leishmania braziliensis infection.

71 cells (PBMCs) from healthy volunteers to L. braziliensis infection.

72 revealed unique immunological features of L. braziliensis infection.

73 e findings uncover a dual role for DCs in L. braziliensis infection: T cell activation by bystander D

74 Leishmania braziliensis infections are often associated with exagge

75 eous leishmaniasis (CL) caused by Leishmania braziliensis is associated with high levels of tumor nec

76 eous leishmaniasis (CL) caused by Leishmania braziliensis is characterized by a strong Th1 response t

77 An unusual feature in L. braziliensis is that the telomeric repeats are often com

78 Leishmania (Viannia) braziliensis is the causative agent of cutaneous and muc

79 Leishmania (subgenus Viannia) braziliensis is the causative agent of mucocutaneous lei

80 iasis, caused in South America by Leishmania braziliensis, is difficult to cure by chemotherapy (prim

81 d SC expression associated with 2 primary L. braziliensis isolates from patients with LCL or MCL.

82 east 70-77% of their sterol from leucine; L. braziliensis, L. donovani and L. tropica apparently prod

83 riTrypDB integrates datasets from Leishmania braziliensis, L. infantum, L. major, L. tarentolae, Tryp

84 tro against Leishmania infantum , Leishmania braziliensis , Leishmania guyanensis , Leishmania amazon

85 omplexes of New World Leishmania (Leishmania braziliensis, Leishmania mexicana, and Leishmania donova

86 suggest that if local therapy for single L. braziliensis lesions is chosen, this treatment is attrac

87 Compared to LRV-1-negative L.V. braziliensis, LRV-1-positive strains of L.V. braziliensi

88 Leishmania braziliensis M2903 contains a highly amplified small chr

89 oll-like receptors (TLRs) are involved in L. braziliensis-mediated DC activation.

90 This killing of L. braziliensis occurred by a gamma interferon-dependent me

91 ed infection with doses of >10(4) Leishmania braziliensis parasites in BALB/c mice.

92 Our understanding of how L. braziliensis parasites interact with dendritic cells (DC

93 We found that DCs cultured with L. braziliensis parasites up-regulated DC activation marker

94 With a dose of 10(7) L. braziliensis parasites, 60 to 70% of the mice developed

95 Mice infected with L. braziliensis plus saliva produced two- to threefold more

96 Herein, L. (V.) braziliensis preparations were standardized to contain 1

97 braziliensis, LRV-1-positive strains of L.V. braziliensis produced a predominant Th2-biased immune re

98 L. braziliensis replication was increased (P < .05) in macr

99 A signature of the L. braziliensis skin lesion was defined, which includes ove

100 s the human immune response, facilitating L. braziliensis survival in vitro, and increases the risk o

101 tion and had a greater ability to control L. braziliensis than cells from patients with CL.

102 oss-protected mice against infection with L. braziliensis that causes mucocutaneous leishmaniasis.

103 he LCTASs are tandemly repeated, while in L. braziliensis the LCTAS is present as a single copy per e

104 .6%) did not have evidence of exposure to L. braziliensis The ratio of infection to disease was 3.2:1

105 in vitro a role for LRV1 in virulence of L. braziliensis, the Leishmania species responsible for the

106 the generation of protective immunity to L. braziliensis, TLR2 seems to have a regulatory role durin

107 In areas where L. braziliensis transmission is endemic, up to 15% of healt

108 en 1992 and 1998 in an area where Leishmania braziliensis transmission is endemic; 8 of the patients

109 w that IL-1beta production in response to L. braziliensis was dependent on NLRP3, caspase-1, and casp